Representative Publications In past years（# co-first author, * Corresponding author）：

[1] Xuejun Wen, Changrong Shi, Xinying Zeng, Liang Zhao, Lanlin Yao, Zhida Liu, Lixia Feng, Deliang Zhang, Jinxiong Huang, Yesen Li, Qin Lin, Haojun Chen, Rongqiang Zhuang, Xiaoyuan Chen*, Xianzhong Zhang*, Zhide Guo*. A paradigm of cancer immunotherapy based on 2-[¹⁸F]FDG and anti-PD-L1 mAb combination to enhance the anti-tumor effect. Clinical Cancer Research 2022, 28:2923-2937.

[2] Lingxin Meng^#, Jianyang Fang^#, Liang Zhao^#, Tingting Wang, Pu Yuan, Zuoquan Zhao, Rongqiang Zhuang, Qin Lin, Haojun Chen*, Xiaoyuan Chen*, Xianzhong Zhang*, Zhide Guo*. Rational design and pharmacomodulation of protein-binding theranostic radioligands for targeting fibroblast activation protein. Journal of Medicinal Chemistry 2022,65:8245-8257.

[3] Xuejun Wen^#, Xinying Zeng^#, Jia Liu, Yiren Zhang,Changrong Shi, Xiaoming Wu, Rongqiang Zhuang, Xiaoyuan Chen*, Xianzhong Zhang*, Zhide Guo*. Synergism of ⁶⁴Cu-labeled RGD with anti-PD-L1 immunotherapy for the long-acting antitumor effect. Bioconjugate Chemistry 2022. doi: 10.1021/acs.bioconjchem.2c00408.

[4] Xuejun Wen^#, Xinying Zeng^#, Changrong Shi, Jia Liu, Yiren Zhang, Mengqi Shi, Jingchao Li, Haojun Chen, Rongqiang Zhuang, Xiaoyuan Chen*, Xianzhong Zhang*, Zhide Guo*. Optimum combination of radiopharmaceuticals-based targeting-triggering-therapy effect and PD-L1 blockade immunotherapy. Advanced Therapeutics 2022. doi: 10.1002/adtp.202200193

[5] Liang Zhao^#, Bo Niu^#, Jianyang Fang^#, Yizhen Pang, Siyang Li, Chengrong Xie, Long Sun, Xianzhong Zhang, Zhide Guo*, Qin Lin, Haojun Chen*. Synthesis, preclinical evaluation, and a pilot clinical PET imaging study of ⁶⁸Ga-labeled FAPI dimer. Journal of Nuclear Medicine 2022, 63:862-868.

[6] Xuejun Wen^#, Pengfei Xu^#, MengqiShi#, Jia Liu, Xinying Zeng, Yiren Zhang, Changrong Shi, Jingchao Li, Zhide Guo*, Xianzhong Zhang*, Pek-Lan Khong*, Xiaoyuan Chen*. Evans blue-modified radiolabeledfibroblast activation protein inhibitor as long-acting cancer therapeutics. Theranostics 2022, 12: 422-433.

[7] Jie Zang^#, Xuejun Wen^#, Rong Lin^#, Xinying Zeng, Chao Wang, Mengqi Shi, Xueyuan Zeng, Jiaying Zhang, Xiaoming Wu, Xianzhong Zhang, Weibing Miao*, Pengfei Xu*, Zhide Guo*, Jingjing Zhang*, Xiaoyuan Chen*. Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [⁶⁸Ga]Ga-FAPI-RGD. Theranostics 2022, 12: 7180-7190.

[8] Xuejun Wen, Changrong Shi, Liu Yang, Xinying Zeng, Xiaoru Lin, Jinxiong Huang, Yesen Li, Rongqiang Zhuang, Haibo Zhu, Zhide Guo*, Xianzhong Zhang*. A radioiodinated FR-β-targeted tracer with improved pharmacokinetics through modification with an albumin binder for imaging of macrophages in AS and NAFL. European Journal of Nuclear Medicine and Molecular Imaging 2022, 49:503-516.

[9] Jianyang Fang^#, Lixia Feng^#, Lingxin Meng^#, Xiaobo Wang, Huanhuan Liu, Lumei Huang, Deliang Zhang, Jindian Li, Rongqiang Zhuang, Zhide Guo*, Xianzhong Zhang*. A novel ¹⁸F-labeled agonist for PET imaging of stimulator of interferon gene expression in tumor-bearing mice. European Journal of Nuclear Medicine and Molecular Imaging 2022. doi: 10.1007/s00259-022-05959-7.

[10] Lumei Huang^#, Jianyang Fang^#, Shouqiang Hong, Huanhuan Liu, Haotian Zhu, Lixia Feng, Rongqiang Zhuang, Xilin Zhao, Zhide Guo*, Xianzhong Zhang*. MicroPET imaging of bacterial infection with nitroreductase-specific responsive ¹⁸F-labelled nitrogen mustard analogues. European Journal of Nuclear Medicine and Molecular Imaging 2022, 49:2645-2654.

[11] Huanhuan Liu^#, Xiaoru Lin^#, Duo Xu, Jingchao Li, Jianyang Fang, Jindian Li, Lingxin Meng, Xinying Zeng, Yesen Li, Jinxiong Huang, Zhide Guo*, and Xianzhong Zhang*. Radioiodinated ethinylestradiol derivatives for estrogen receptor targeting breast cancer imaging. ACS Medicinal Chemistry Letters 2022, 13:203-210.

[12] Yiren Zhang, Xuejun Wen, Yanjie Wang, Xia Yang, Yingxi Chen, Xinying Zeng, Yesen Li, Jinxiong Huang, Zhide Guo*, Xianzhong Zhang*. Longitudinal MicroSPECT Imaging of Systemic Sclerosis Model Mice with ^99mTc-HYNFA via FR Targeting. Molecular Pharmaceutics 2022, doi: 10.1021/acs.molpharmaceut.2c00717

[13] Jindian Li^#, Yingxi Chen^#, Chenyu Peng^#, Xingfang Hong^#, Huanhuan Liu, Jianyang Fang, Rongqiang Zhuang, Weimin Pan, Deliang Zhang*, Zhide Guo*, Xianzhong Zhang*. Micro-SPECT Imaging of Acute Ischemic Stroke with Radioiodinated Riboflavin in Rat MCAO Models via Riboflavin Transporter Targeting. ACS Chemical Neuroscience 2022, 13:1966-1973.

[14] Lanlin Yao^#, Xuejun Wen^#, Wei Guo, Jianyang Fang, Xianzhong Zhang, Zhide Guo*, Jinxiong Huang*, Yesen Li¹*. A novel radiolabeled TMTP1 for long-acting hepatocellular carcinoma therapeutics. Molecular Pharmaceutics 2022,19, 9, 3178-3186.

[15] Lixia Feng, Jianyang Fang, Xinying Zeng, Huanhuan Liu, Jingru Zhang, Zhide Guo*, Rongqiang Zhang*, Xianzhong Zhang*. ⁶⁸Ga-labeled maleimide for blood pool and lymph PET imaging throughcovalent bonding to serum albumin in vivo. ACS Omega 2022, 7:28597-28604.

[16] Xuejun Wen, Xueyuan Zeng, Xingxing Cheng, Xinying Zeng, Jia Liu, Yiren Zhang, Yesen Li, Haojun Chen, Jinxiong Huang*, Zhide Guo*, Xiaoyuan Chen*, Xianzhong Zhang*. PD-L1-targeted radionuclide therapy combined with αPD-L1 antibody immunotherapy synergistically improves the antitumor effect. Molecular Pharmaceutics 2022, 19:3612-3622.

[17] Duo Xu^#, Xiaoru Lin^#, Xinying Zeng^#, Xuejun Wen, Jingchao Li, Yesen Li, Jinxiong Huang, Xiaoyuan Chen, Zhide Guo*, Xianzhong Zhang*. Radioiodinated 4-(p-iodophenyl) butanoic acid modified estradiol derivative for ER targeting SPECT imaging. Analytical Chemistry 2021, 93:13998-14006.

[18] Jingchao Li^#, Shuqi Dai^#, Ruixue Qin, Changrong Shi, Jiang Ming, Xinying Zeng, Xuejun Wen, Rongqiang Zhuang, Xiaoyuan Chen*, Zhide Guo*, Xianzhong Zhang*. Ligand Engineering of Titanium-Oxo Nanoclusters for Cerenkov Radiation-Reinforced Photo/Chemodynamic Tumor Therapy. ACS Appl Mater Interfaces 2021, 13: 54727-54738.